Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products

Pozzoli, M; Ong, HX; Morgan, L; Sukkar, M; Traini, D; Young, PM; Sonvico, F

Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products

Pozzoli, M

Ong, HX Morgan, L Sukkar, M

Traini, D Young, PM Sonvico, F

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107 pp. 223 - 233
Issue Date:: 2016-10-01

Closed Access

	Filename	Description	Size
	1-s2.0-S0939641116302867-main-2.pdf	Published Version	1.97 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Pozzoli, M https://orcid.org/0000-0002-2471-6666	en_US
dc.contributor.author	Ong, HX	en_US
dc.contributor.author	Morgan, L	en_US
dc.contributor.author	Sukkar, M https://orcid.org/0000-0003-4591-2399	en_US
dc.contributor.author	Traini, D	en_US
dc.contributor.author	Young, PM	en_US
dc.contributor.author	Sonvico, F https://orcid.org/0000-0001-7372-1456	en_US
dc.date.available	2016-07-08	en_US
dc.date.issued	2016-10-01	en_US
dc.identifier.citation	European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107 pp. 223 - 233	en_US
dc.identifier.issn	0939-6411	en_US
dc.identifier.uri	http://hdl.handle.net/10453/48385
dc.description.abstract	© 2016 Elsevier B.V. The aim of this study was to incorporate an optimized RPMI2650 nasal cell model into a 3D printed model of the nose to test deposition and permeation of drugs intended for use in the nose. The nasal cell model was optimized for barrier properties in terms of permeation marker and mucus production. RT-qPCR was used to determine the xenobiotic transporter gene expression of RPMI 2650 cells in comparison with primary nasal cells. After 14 days in culture, the cells were shown to produce mucus, and to express TEER (define) values and sodium fluorescein permeability consistent with values reported for excised human nasal mucosa. In addition, good correlation was found between RPMI 2650 and primary nasal cell transporter expression values. The purpose-built 3D printed model of the nose takes the form of an expansion chamber with inserts for cells and an orifice for insertion of a spray drug delivery device. This model was validated against the FDA glass chamber with cascade impactors that is currently approved for studies of nasal products. No differences were found between the two apparatus. The apparatus including the nasal cell model was used to test a commercial nasal product containing budesonide (Rhinocort, AstraZeneca, Australia). Drug deposition and transport studies on RPMI 2650 were successfully performed. The new 3D printed apparatus that incorporates cells can be used as valid in vitro model to test nasal products in conditions that mimic the delivery from nasal devices in real life conditions.	en_US
dc.relation.ispartof	European Journal of Pharmaceutics and Biopharmaceutics	en_US
dc.relation.isbasedon	10.1016/j.ejpb.2016.07.010	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Nasal Mucosa	en_US
dc.subject.mesh	Cell Line	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Fluorescein	en_US
dc.subject.mesh	Carrier Proteins	en_US
dc.subject.mesh	Xenobiotics	en_US
dc.subject.mesh	Culture Media	en_US
dc.subject.mesh	Microscopy, Electron	en_US
dc.subject.mesh	Models, Biological	en_US
dc.subject.mesh	Printing, Three-Dimensional	en_US
dc.title	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products	en_US
dc.type	Journal Article
utslib.citation.volume	107	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	107	en_US

Abstract:

© 2016 Elsevier B.V. The aim of this study was to incorporate an optimized RPMI2650 nasal cell model into a 3D printed model of the nose to test deposition and permeation of drugs intended for use in the nose. The nasal cell model was optimized for barrier properties in terms of permeation marker and mucus production. RT-qPCR was used to determine the xenobiotic transporter gene expression of RPMI 2650 cells in comparison with primary nasal cells. After 14 days in culture, the cells were shown to produce mucus, and to express TEER (define) values and sodium fluorescein permeability consistent with values reported for excised human nasal mucosa. In addition, good correlation was found between RPMI 2650 and primary nasal cell transporter expression values. The purpose-built 3D printed model of the nose takes the form of an expansion chamber with inserts for cells and an orifice for insertion of a spray drug delivery device. This model was validated against the FDA glass chamber with cascade impactors that is currently approved for studies of nasal products. No differences were found between the two apparatus. The apparatus including the nasal cell model was used to test a commercial nasal product containing budesonide (Rhinocort, AstraZeneca, Australia). Drug deposition and transport studies on RPMI 2650 were successfully performed. The new 3D printed apparatus that incorporates cells can be used as valid in vitro model to test nasal products in conditions that mimic the delivery from nasal devices in real life conditions.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/48385